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Objectives: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is widely 
used to treat neutropenia during cytotoxic chemotherapy. The optimal scheduling of rhG-CSF 
is unknown and can hardly be tested in clinical studies due to numerous therapy parameters 
affecting outcome (chemotherapeutic regimen, rhG-CSF schedules, individual covariables). 
Motivated by biomathematical model simulations, we aim to investigate different rhG-CSF 
schedules in a preclinical chemotherapy mouse model.
Methods: The time course of hematotoxicity was studied in CD-1 mice after cyclophosphamide 
(CP) administration. Filgrastim was applied concomitantly in a 2 × 3-factorial design of two 
dosing options (2 × 20 μg and 4 × 10 μg) and three timing options (directly, one, and two days 
after CP). Alternatively, a single dose of 40 μg pegﬁ  lgrastim was applied at the three timing 
options. The resulting cytopenia was compared among the schedules.
Results: Dosing and timing had a signiﬁ  cant inﬂ  uence on the effectiveness of ﬁ  lgrastim sched-
ules whereas for pegﬁ  lgrastim the timing effect was irrelevant. The best ﬁ  lgrastim and pegﬁ  l-
grastim schedules exhibited equivalent toxicity. Monocytes dynamics performed analogously 
to granulocytes. All schedules showed roughly the same lymphotoxicity.
Conclusion: We conclude that effectiveness of ﬁ  lgrastim application depends heavily on its 
scheduling during chemotherapy. There is an optimum of timing. Dose splitting is better than 
concentrated applications. Effectiveness of pegﬁ  lgrastim is less dependent on timing.
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Introduction
Conventional multi-drug, multi-cycle cytotoxic chemotherapy is still a major therapy 
option for many chemosensitive cancers and hematologic malignancies. Several 
studies have shown a clear relationship between dose density (deﬁ  ned as drug dose 
per time interval) and outcome (tumor control or survival).1–6 Accordingly, in some 
prospective clinical trials it has been shown that an overall increment in dose density 
could improve outcome (breast cancer,7,8 high-grade non-Hodgkin’s lymphoma,9–11 
Hodgkin’s disease,12 transitional cell carcinoma,13 small-cell lung cancer14).
Because of a low tissue speciﬁ  city of cytotoxic drugs, intensiﬁ  ed chemotherapies 
increase the risk of side effects eg, with respect to the hematological system. Among 
these side effects common toxicity criteria (CTC) grade 3 and 4 neutropenia is espe-
cially problematic because of increased incidence of infections, hospitalization, antibi-
otic treatment, necessity to reduce therapy intensity and therapy-associated deaths.15–22 
For prophylaxis or amelioration of neutropenia, recombinant human granulocyte 
colony-stimulating factor (rhG-CSF) is applied routinely.20,23–26
There are two major derivatives of rhG-CSF currently available: ﬁ  lgrastim and 
its pegylated counterpart, pegﬁ  lgrastim. ﬁ  lgrastim is rhG-CSF with a short half-life Biologics: Targets & Therapy 2009:3 28
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necessitating repeated applications per chemotherapy cycle. 
It is considered to be lineage speciﬁ  c and enhances granu-
lopoiesis by mitotic activation of progenitors and precur-
sors and by accelerated maturation.27–29 It is also assumed 
that rhG-CSF reduces the rate of apoptosis in postmitotic 
maturing cells which induces an instantaneous increment 
in peripheral granulocyte counts in healthy subjects shortly 
after application.30,31
Filgrastim is degraded in vivo by unspeciﬁ  c renal elimina-
tion32,33 and speciﬁ  cally, via G-CSF receptors or neutrophil 
elastase.34–39 In comparison, the rhG-CSF derivative pegﬁ  l-
grastim has a prolonged half-life in vivo due to the reduction 
of renal clearance.40–42 Only one injection of pegﬁ  lgrastim is 
required during one cycle of chemotherapy.43 It is believed 
that pegﬁ  lgrastim has the same mechanisms of action as ﬁ  l-
grastim.44 Clinical trials have shown that multiple injections 
of ﬁ  lgrastim and single injections of pegﬁ  lgrastim are roughly 
equivalent with respect to prophylaxis and treatment of neu-
tropenia and infections.20,45–47 One meta-analysis showed a 
small advantage for pegﬁ  lgrastim regarding the rate of febrile 
neutropenia.48 On the other hand, the exact pharmacokinetic 
and dynamic properties of pegﬁ  lgrastim in comparison to 
ﬁ  lgrastim have not yet been analyzed well enough.
Because of the high potency of G-CSF with respect to the 
stimulation of granulopoiesis with different modes of action 
and the strong relationship between neutrophil counts and 
drug clearance, the application of G-CSF after bone marrow 
toxic chemotherapy results in a complex dynamic behavior 
of neutrophil cell counts which cannot easily be predicted. 
Furthermore, it is impossible to test all schedules of rhG-CSF 
application within the framework of clinical trials because 
of the large number of combinations of different dosing 
and timing options of both rhG-CSF and chemotherapeutic 
agents as well.
Based on a biomathematical model of human granulo-
poiesis, we predicted that the scheduling of multiple injec-
tions of ﬁ  lgrastim can be optimized regarding the degree of 
leukotoxicity.49,50 We suppose that there are optima of both 
dosing and timing of ﬁ  lgrastim as well which depend on the 
applied chemotherapeutic regimen. This model can be used 
for the planning of clinical trials. Recently we constructed a 
similar preliminary model for the murine situation in order 
to validate our modeling approach in an animal model. We 
predicted that timing of pegﬁ  lgrastim could be optimized as 
well in order to reduce granulotoxicity after cyclophospha-
mide (CP)-induced neutropenia. We also predicted that the 
timing effect is abrogated for highly dosed pegﬁ  lgrastim 
(publication in process).
Although there are several publications regarding the 
action of rhG-CSF in combination with chemotherapy, the 
lack of data does not permit to make more precise predic-
tions of optimal schedules even in the murine situation: 
The application of cytotoxic drugs such as CP in mice 
has been studied extensively.51 Furthermore, there are 
several studies addressing the combined application of 
G-CSF and cytotoxic drugs or radiation.44,52–56 Bauhofer and 
colleagues57 investigated the effect of G-CSF schedules in 
a septic rat model. Misaki and colleagues58 analysed differ-
ent timings of G-CSF prior to CP application. Yankelevich 
and colleagues59 addressed the effect of timing of ﬁ  lgrastim 
on bone marrow cellularity but did not measured the time 
course in the nadir phase of circulating cells. Grigg and 
colleagues60 optimized G-CSF scheduling with respect to 
stem cell harvest. However, to our knowledge there is no 
animal study which aims to determine the best scheduling 
of ﬁ  lgrastim and pegﬁ  lgrastim for prophylaxis of resulting 
blood cytopenia. Furthermore, published data does not fulﬁ  ll 
our requirements for a systems–biologic modeling approach 
since multiple concomitant measurements of granulocytes, 
monocytes, lymphocytes, and G-CSF plasma concentrations 
are required in narrow time intervals after the application 
of cytotoxic drugs and under different G-CSF schedules 
(compare49,50).
Hence, in this report we explore the potential of differ-
ent G-CSF schedules for ﬁ  lgrastim and pegﬁ  lgrastim in a 
chemotherapy mouse model. Our experiments have two 
major purposes: to assess and compare the hematotoxicity 
(especially neutropenia) of different application schedules in 
a factorial study design and to provide an improved data base 
for our ongoing systems – biologic modeling work.
Methods
Experimental interventions
Female, 8-week-old outbred Hsd:ICR mice (CD-1®, Harlan 
Sprague Dawley, Inc., obtained from a breeding stock from 
Charles River Breeding Laboratories) were used for this 
study. The mice were maintained in a deﬁ  ned ﬂ  ora animal 
facility.
The mice were injected either intraperitoneally with a 
chemotherapeutical agent at an injection volume of 200 μl 
(cyclophosphamid 450 mg/kg (12 mg) [Endoxan, Baxter] 
or subcutaneously between the scapulae with rhG-CSF deri-
vates at an injection volume of 100 μl (ﬁ  lgrastim 10 μg or 
20 μg [Neupogen, Amgen] or pegﬁ  lgrastim 40 μg [Neulasta, 
Amgen]). All mass data regarding rhG-CSF applications are 
given as protein mass.Biologics: Targets & Therapy 2009:3 29
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After a combined treatment of these study drugs, 
peripheral blood of the mice was taken from the tail vein 
at specified time points. Blood was collected through 
heparinized capillaries (Rolf Greiner Biochemica) and 
transferred to heparinized tubes (Heparin-Natrium-25000, 
Ratiopharm). Rates of red blood cells, white blood cells, 
platelets and the relative and absolute contents of lympho-
cytes, monocytes, and granulocytes were determined by using 
an Animal Blood Counter (scil Vet abc, SCIL animal care 
company), which had been calibrated for mouse blood.
The levels of G-CSF present in plasma were assessed 
using the human G-CSF cytometric bead array kit (CBA, BD 
Biosciences, Pharmingen). Data were acquired on a FACS 
Calibur (Becton Dickinson) and analysed using the FCAP 
Array software (BD Biosciences, Pharmingen).
All measurements were supported by at least ﬁ  ve mice.
Study design
A CP dose was chosen which results in a deep but revers-
ible nadir of granulocyte cell counts in mice after a single 
application.
In order to analyse the effect of a concentrated versus a 
split application of G-CSF, we applied two doses of 20 μg 
ﬁ  lgrastim (2 × 20 μg) in comparison to four doses of 10 μg 
ﬁ  lgrastim (4 × 10 μg) on consecutive days after CP applica-
tion. Applications were started directly (1 h later), one or 
two days after CP application in order to evaluate the effect 
of timing. Alternatively, we applied a ﬁ  xed single dose of 
40 μg pegﬁ  lgrastim directly (1 h later), one or two days after 
CP application.
According to our design, we applied the same total 
protein mass of G-CSF in all experiments, which allows 
comparisons to be made regarding the effectiveness of dif-
ferent schedules.
Evaluation of toxicity
Hematotoxicity of an experimental setting was evaluated 
on the basis of the time course of the cell counts within the 
nadir phase for each single mouse separately. Three aggre-
gated measures of toxicity were used in clinical practice; 
the minimal cell count (MCC), the duration of cytopenia 
(DoC), which is the total time below the normal cell count 
(NCC), and the area over the curve (AOC), deﬁ  ned as the 
area between NCC and the time course. For granulocytes 
it has been shown that MCC and DoC are both related to 
infections.61 The MCC can be estimated by assessing several 
time points in the nadir phase of cell counts. The DoC is most 
difﬁ  cult to determine because the exact crossing points of 
time course and NCC can hardly be detected. The AOC is an 
integrated measure of MCC and DoC which can be estimated 
more easily by interpolation of the measurements in the nadir 
phase and integration of the resulting curves. No exact time 
points of crossing with the NCC are required to get a good 
estimate for AOC because it is mainly determined on the 
basis of the period with low cell counts.
Statistical analysis
Cell counts were logarithmized for all analyses to obtain 
normally distributed quantities. Therefore, we present geo-
metric means and standard deviations (SD) for cell counts 
or G-CSF plasma concentrations throughout.
NCC is required for the calculation of AOC and has been 
determined for each cell line on the basis of all mice of all 
experiments. The MCC and AOC of single mice have been 
determined as described above. The effects of G-CSF deriva-
tive and its dosing and timing schedule on MCC and AOC 
have been calculated by ANOVA. For this purpose, MCC 
and AOC were adjusted for the corresponding initial values 
of cell counts (prior to intervention) since these values were 
often predictive for the nadir phase. In the case of global 
signiﬁ  cance, contrasts were estimated for the correspond-
ing quantities.
The occurrence of nadir was compared between the 
groups using the Jonckheere–Terpstra test for trends.
The calculation of the AOC was performed using the 
computational software package Matlab 7.0.4.365 (The 
MathWorks, Natick, MA, USA). Statistical analyses were 
performed using the statistical software package SAS 9.1 
(SAS Institute Inc., Cary, NC, USA) and the statistical soft-
ware package “R” (see http://www.r-project.org/62).
Results
Normal values
On the basis of a total of 80 animals we determined nor-
mal values for granulocytes (mean 2.3 * 106 ml−1, SD 1.7), 
monocytes (mean 4.9 * 105 ml-1, SD 1.6), lymphocytes (mean 
9.3 * 106 ml−1, SD 1.5), thrombocytes (mean 9.7 * 108 ml−1, 
SD 1.3), and red blood cells (mean 8.2 * 109 ml−1, SD 1.2). 
These values were used to assess the hematotoxicity of dif-
ferent G-CSF schedules in the next steps.
Time courses after application
of 12 mg CP alone
Granulocytes
Application of a single dose of 12 mg CP resulted in a deep 
but reversible decline of granulocytes (see Figure 1A). Biologics: Targets & Therapy 2009:3 30
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The lowest granulocyte counts were measured between 72 h 
and 108 h after CP. Granulocytes have been recovered at 
132 h followed by a time period of approximately ﬁ  ve days 
with overcompensation. The rate of granulocytes with respect 
to the total cell count of white blood cells was lower than 
normal in the nadir phase of granulocytes. It was higher than 
normal shortly after CP and during the period of recovery 
(see Figure 1B).
Monocytes
Monocyte nadir occurred between 84 h and 120 h after CP. 
Recovery was reached at 156 h followed by a ﬁ  ve-day period 
of overcompensation (see Figure 1A). Hence, monocyte 
dynamics are similar to granulocyte dynamics. The same 
holds for the rate of monocytes (see Figure 1B).
Lymphocytes
Lymphocyte counts also expressed a deep nadir with a pla-
teau of low counts lasting between 36 h and 120 h after CP 
(see Figure 1A). Recovery was reached approximately 180 h 
after CP. We observed a second deep nadir of lymphocytes 
at 312 h. The rate of lymphocytes was higher than normal 
in the nadir phase of granulocytes. At all other time points, 
the rate was lower than normal (see Figure 1B).
Other lineages
The time course of thrombocytes showed no thrombopenic 
phase (data not shown), indicating that the CP application is 
not suitable to study chemotherapy-induced thrombopenia 
in the mouse. Red blood cells showed only a mild decrease 
after CP, and therefore, they were not analyzed for toxicity 
(data not shown). Hence, we restricted our attention to granu-
locytes, monocytes, and lymphocytes in the following.
Time courses after combined application 
of 12 mg CP and ﬁ  lgrastim in different 
schedules
Granulocytes
The time courses of granulocytes and corresponding G-CSF 
plasma concentrations for the timing options of ﬁ  lgrastim 
are shown in Figures 2 and 3, separately for the two dosing 
options (two times 20 μg versus four times 10 μg). Due to the 
short half-life of ﬁ  lgrastim in vivo, G-CSF plasma concentra-
tions drop quickly after stopping G-CSF applications.
CP in combination with the different ﬁ  lgrastim schedules 
also resulted in a clear granulopenic phase where the lowest 
granulocyte counts were measured between 60 h and 108 h 
(see Table 1). We recognized that nadirs in the day 0 sched-
ules appear signiﬁ  cantly earlier than in the other schedules 
(p  0.0001).
MCC and AOC were calculated for all mice individually 
and were adjusted for the initial counts. Statistics of these 
quantities can be read in Table 2 for all schedules and in 
comparison to the results obtained without G-CSF support.
With respect to MCC the best ﬁ  lgrastim schedule was 
day 1, 4 × 10 μg which was signiﬁ  cantly better than all other 
schedules. The worst one was day 0, 2 × 20 μg which was 
even worse than no G-CSF at all. Global testing of differ-
ences between the schedules was signiﬁ  cant (p = 0.0047). 
Independent of timing, the scheduling for 4 × 10 μg was 
signiﬁ  cantly better than 2 × 20 μg (p = 0.048). Independent 
of dosing, the timing on day 0 was signiﬁ  cantly worse than 
the timing on day 1 (p = 0.0014). Other differences with 
respect to timing were not signiﬁ  cant.
With respect to AOC the best ﬁ  lgrastim schedule again 
was day 1, 4 × 10 μg. The worst one was day 0, 2 × 20 μg 
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with toxicity comparable to no G-CSF application at all. 
For the 2 × 20 μg dosing schedule it was best to apply 
ﬁ  lgrastim later, on day 2. Global testing of differences 
between schedules was signiﬁ  cant (p  0.0001). Indepen-
dent of timing, the schedules 4 × 10 μg were signiﬁ  cantly 
better than 2 × 20 μg (p  0.0001). Independent of dosing, 
the timing day 0 was signiﬁ  cantly worse than the timing 
day 2 (p = 0.020).
Monocytes
CP in combination with the ﬁ  lgrastim schedules resulted 
in a clear monocytopenic phase. The lowest counts were 
measured between 60 h and 132 h (see Table 1). In the day 
0 schedules the nadir occurred earlier than in the day 1 or 
day 2 schedules (p = 0.0004).
MCC and AOC statistics for monocytes can be found in 
Table 2. With respect to MCC the best ﬁ  lgrastim schedule was 
day 1, 4 × 10 μg. The worst schedule was day 0, 2 × 20 μg. 
Global testing was signiﬁ  cant (p = 0.0005). Independent of 
timing, the schedules 4 × 10 μg were signiﬁ  cantly better than 
2 × 20 μg (p = 0.049). Independent of dosing, the timing day 0 
was signiﬁ  cantly worse than the timing day 1 (p = 0.0017).
For AOC the best scheduling again was day 1, 4 × 10 μg, 
the worst was day 2, 2 × 20 μg. Global test of differences 
was signiﬁ  cant (p = 0.010). However, there are no signiﬁ  cant 
general dosing and timing effects.
Lymphocytes
CP in combination with the different G-CSF schedules also 
resulted in a clear lymphopenic phase where the lowest count 
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was reached between 36 h and 108 h (see Table 1). Again, 
the occurrence of nadir is earlier in the day 0 schedules in 
comparison to the day 1 and 2 schedules (p = 0.0007).
MCC and AOC statistics of lymphocytes can be read from 
Table 2. Once more, with respect to MCC the best ﬁ  lgrastim 
schedule was day 1, 4 × 10 μg. The worst schedule was day 
0, 4 × 10 μg. However, global test of differences between 
schedules was not signiﬁ  cant (p = 0.059). Hence, contrasts 
were not calculated. For AOC the best schedule was day 1, 4 × 
10 μg, the worst was day 0, 4 × 10 μg. Again, global test was 
not signiﬁ  cant (p = 0.28). Contrasts were not calculated.
These results indicate that the different ﬁ  lgrastim sched-
ules had no signiﬁ  cant impact on lymphocyte dynamics.
Time course after combined application 
of 12 mg CP and pegﬁ  lgrastim in different 
schedules
Granulocytes
The time courses of granulocytes and corresponding G-CSF 
plasma concentrations of the different pegﬁ  lgrastim timing 
schedules are shown in Figure 4. Due to improved pharma-
cokinetic properties of pegﬁ  lgrastim, plasma concentrations 
dropped much later than for ﬁ  lgrastim applications. The nadir 
of granulocytes appeared between 60 h and 84 h (Table 1). 
Again, a shift towards an earlier occurrence of nadir could 
be observed in the day 0 group (p = 0.0064).
With respect to MCC the best pegﬁ  lgrastim timing was 
day 1 (Table 2). But there were no signiﬁ  cant differences 
between the pegﬁ  lgrastim schedules and the control group 
with no G-CSF support (p = 0.081).
With respect to AOC the best pegﬁ  lgrastim timing was 
day 1. Global testing of differences between the schedules 
was signiﬁ  cant (p  0.0001). Pegﬁ  lgrastim schedules were 
always better than no G-CSF (p  0.0001 for all timing 
options). On the other hand there were no signiﬁ  cant differ-
ences between the three timing options. Hence, the timing 
options can be considered to be equivalent with respect to 
both MCC and AOC.
Monocytes
The nadir was reached between 60 h and 108 h (Table 1). 
In the day 0 schedule, the nadir occurred earlier than in the 
other schedules (p = 0.0053).
Pegﬁ  lgrastim timing on day 1 was best with respect to 
MCC (Table 2). All three pegﬁ  lgrastim schedules were sig-
niﬁ  cantly better than the control group without G-CSF sup-
port (day 0: p = 0.013, day 1: p = 0.0024, day 2: p = 0.013), 
but there were no signiﬁ  cant differences between the peg-
ﬁ  lgrastim timings.
Global testing was also signiﬁ  cant for AOC (p  0.0001). 
Pegﬁ  lgrastim timing at day 1 was the best. All pegﬁ  lgrastim 
schedules were better than no G-CSF (all p  0.0001). On 
the other hand there were no signiﬁ  cant differences between 
the three timing options.
Consequently, the three timing options can be considered 
to be equivalent with respect to both MCC and AOC.
Table 1 Nadir times of granulocytes, monocytes, and lymphocytes: Number of animals reaching the nadir at speciﬁ  ed time points are 
presented for all cell lines and G-CSF schedules
G-CSF 
Schedule
Nadir times
Pegﬁ  lgrastim Filgrastim
1 × 40 μg4   × 10 μg2   × 20 μg
Day 0
(N = 8)
Day 1 
(N = 8)
Day 2 
(N = 8)
Day 0 
(N = 10)
Day 1 
(N = 5)
Day 2 
(N = 5)
Day 0 
(N = 10)
Day 1 
(N = 5)
Day 2 
(N = 5)
Granulocytes 60 h 5 0 2 7 0 0 4 0 0
84 h 3 8 6 3 5 5 6 4 5
108 h 0 0 0 0 0 0 0 1 0
Monocytes 60 h 4 0 1 4 0 0 4 0 0
84 h 4 8 3 5 4 5 6 3 2
108 h 0 0 4 1 0 0 0 2 2
132 h 0 0 0 0 1 0 0 0 1
Lymphocytes 36 h 0 0 0 0 0 0 2 0 0
60 h 6 1 3 9 3 1 6 1 1
84 h 2 6 3 0 1 4 1 2 3
108 h 0 1 2 1 1 0 1 2 1Biologics: Targets & Therapy 2009:3 33
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Lymphocytes
For lymphocytes the nadir was reached between 60 h and 
108 h (Table 1). A shift towards earlier nadirs for the day 0 
schedule could be detected (p = 0.0094).
With respect to MCC and AOC the lymphotoxicity was 
not signiﬁ  cantly different between the schedules, ie, between 
the control group and the three timing options of pegﬁ  lgras-
tim (MCC p = 0.76, AOC p = 0.85).
Comparison of pegﬁ  lgrastim and ﬁ  lgrastim
For granulocytes, we compared the best schedule for ﬁ  lgras-
tim (day 1, 4 × 10 μg) with the best schedule for pegﬁ  lgrastim 
(day 1) and found no signiﬁ  cant differences with respect to 
MCC (p = 0.39) and AOC (p = 0.33). The same holds true 
for monocytes MCC (p = 0.26) and AOC (p = 0.27).
Discussion
In the present study we aimed to explore the potential of dif-
ferent ﬁ  lgrastim and pegﬁ  lgrastim application schedules of 
constant total doses after CP-induced hematotoxicity. Major 
conclusions are that the scheduling of ﬁ  lgrastim is crucial 
for the recovery of granulocytes. There is an optimal timing. 
Splitting of the dose over several injections is better than 
more concentrated application. Pegﬁ  lgrastim application is 
Table 2 Characteristics for the granulotoxicity, monocytotoxicity, and lymphotoxicity for all schedules considered. We present arithmetic 
mean and standard deviation (in parentheses) for logarithmized MCC and AOC adjusted for initial cell counts. Both low MCC and 
high AOC indicate high toxicity as well. Grey areas indicate the schedules with corresponding lowest toxicity for both ﬁ  lgrastim and 
pegﬁ  lgrastim as well
G-CSF 
schedule
Without Pegﬁ  lgrastim Filgrastim
1 × 40 μg4   × 10 μg2   × 20 μg
Day 0 Day 1 Day 2 Day 0 Day 1 Day 2 Day 0 Day 1 Day 2
Granulocytes MCC 
(log ml−1)
13.0 
(0.35)
13.4 
(0.59)
13.5 
(0.30)
13.5 
(0.52)
13.1 
(0.22)
13.7 
(0.44)
13.1 
(0.08)
12.8 
(0.33)
13.2 
(0.21)
13.2 
(0.52)
AOC
(h)
131.0 
(36.7)
48.0 
(28.4)
46.4 
(19.9)
46.8 
(19.7)
79.5 
(26.6)
39.6 
(15.4)
44.6 
(2.7)
111.6 
(36.0)
108.7 
(22.8)
90.2 
(17.1)
Monocytes MCC 
(log ml−1)
11.1 
(0.42)
11.6 
(0.37)
11.7 
(0.30)
11.6 
(0.20)
11.5 
(0.22)
11.9 
(0.26)
11.4 
(0.11)
11.1 
(0.37)
11.5 
(0.23)
11.6 
(0.30)
AOC
(h)
158.8 
(36.1)
90.5 
(42.1)
81.1 
(19.3)
83.7 
(20.0)
135.5 
(21.5)
98.4 
(15.5)
99.9 
(13.7)
129.4 
(35.6)
125.0 
(31.3)
142.3 
(26.4)
Lymphocytes MCC 
(log ml−1)
14.6 
(0.43)
14.5 
(0.40)
14.4 
(0.32)
14.6 
(0.19)
14.0 
(0.44)
14.8 
(0.15)
14.7 
(0.21)
14.3 
(0.34)
14.5 
(0.25)
14.2 
(1.1)
AOC
(h)
172.9 
(59.2)
162.9 
(71.3)
164.8 
(20.4)
146.8 
(34.0)
217.0 
(53.3)
169.6 
(28.6)
182.6 
(30.3)
202.2 
(24.8)
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(25.9)
203.5 
(39.3)
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Figure 4 A) Granulocyte count in mice after application of a single dose of 12 mg CP and one dose of pegﬁ  lgrastim (40 μg) directly, one or two days after CP. Each point 
represents the geometric mean of eight mice. Bars correspond to the geometric standard deviation. Dashed line represents the population geometric mean in untreated mice. 
For comparison, grey line of no G-CSF application is plotted as in Figure 2. B) Corresponding G-CSF plasma concentrations.Biologics: Targets & Therapy 2009:3 34
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more robust. No effects of different timing were found for 
the relatively high dose used. The best ﬁ  lgrastim schedule 
is equivalent to pegﬁ  lgrastim. Monocytes react concomi-
tant to granulocytes. Lymphotoxicity was not affected by 
the G-CSF schedules. Starting G-CSF treatment directly 
after CP results in earlier occurrence of the nadir of all 
cell counts. However, toxicity was not necessarily higher. 
Daily concomitant measurements of both, granulocytes, 
monocytes, lymphocytes, and G-CSF plasma concentrations 
as well are available now and can be used to improve our 
biomathematical models.
For the experiments, we used outbred CD1 mice in order 
to allow similar variances of toxic reactions as in the human 
situation.
We applied 12 mg of CP which resulted in a deep but 
reversible nadir of granulocytes, monocytes and lympho-
cytes. Red blood cell counts could not be analyzed with 
respect to hematotoxicity, since the long half-life of eryth-
rocytes prevents anemia in this moderately cytotoxic che-
motherapy setting as far as possible. Platelets also showed 
no signiﬁ  cant reduction in cell counts in accordance with 
earlier observations.63,64
Concomitantly to the CP administration, we applied 
G-CSF in different dosing and timing schedules. Filgrastim 
was administered in a 2 × 3-factorial design with two dosing 
variants (2 × 20 μg daily and 4 × 10 μg daily) and with three 
timing variants (directly, 1 day, 2 days after CP). Pegﬁ  lgras-
tim was administered with a ﬁ  xed dose of 40 μg directly, 1 day 
or 2 days after CP. Numerous evidence has been collected 
about a clear dose response relationship for both ﬁ  lgrastim 
and pegﬁ  lgrastim (ﬁ  lgrastim: for example,34,65 pegﬁ  lgras-
tim55,66). Hence, there is no question that a higher total dose 
will result in lower toxicity when applied properly. Therefore, 
in our study we kept the parameter of total dose constant in 
order to analyze the remaining effects of different schedules. 
We used a relatively high dose of ﬁ  lgrastim and pegﬁ  lgras-
tim in order to obtain informative time courses of cytokine 
concentrations for later pharmacokinetic modeling.
In order to compare cytopenia between the G-CSF sched-
ules we used two surrogate markers. It has been shown that 
MCC of granulocytes is related to adverse events in cancer 
therapy of humans.61 Furthermore, in clinical studies it is used 
to deﬁ  ne grades of hematotoxicity. However, we showed that 
variance of MCC was small between schedules. Therefore, 
we also considered AOC which is a combined measure of 
MCC and DoC. In general AOC had more power than MCC 
to differentiate between schedules. On the other hand, in 
our data AOC is strongly (inversely) correlated to MCC 
(granulocytes: r = −0.78, monocytes r = −0.75, lymphocytes 
r = −0.86, Pearson’s correlation coefﬁ  cient). Both markers 
of toxicity are based on the pure number of cells and not on 
their function, which is a limitation of our study.67
First, we analyzed the granulocyte dynamics of the 
schedules. For ﬁ  lgrastim, the schedule on day 1, 4 × 10 μg 
was best with respect to both MCC and AOC. The worst 
schedule was day 0, 2 × 20 μg which exhibited toxicity 
comparable to no G-CSF at all. Dose splitting 4 × 10 μg 
was always signiﬁ  cantly better than 2 × 20 μg, independent 
of timing. Furthermore, the timing at day 0 was always sig-
niﬁ  cantly worse than later timing, independent of dosing. It 
is interesting to explain these observations in more detail. 
The effect of dose splitting could be favorable because of 
the observation that dose response curves for ﬁ  lgrastim are 
saturated at a certain level.34 In accordance, Tanaka and col-
leagues68 showed that subcutaneous injection with a lower 
initial concentration but higher sustained concentration is 
more effective than intravenous injection. The effect of tim-
ing can be understood by two competitive processes. At ﬁ  rst, 
stimulation of bone marrow, including increased proliferation 
and maturation should start early. On the other hand, bone 
marrow reserve is activated directly after G-CSF application 
causing an immediate increment of cell counts.30,31,69 This 
should best happen directly in the nadir phase of cell counts. 
Hence, we suppose that there is an optimum between early 
and late timing which cannot easily be predicted. This has 
also been found qualitatively by model simulations of our 
biomathematical model of human granulopoiesis.50,70 For 
the dosing 4 × 10 μg the optimum was day 1. Interestingly, 
for the dosing 2 × 20 μg it might be better to start at day 2. 
In our experiments the timing day 0 was too early, resulting 
in an earlier nadir and worse recovery. Clinicians also do 
not recommend starting G-CSF directly after chemotherapy 
because of possible interactions with chemotherapy.71 How-
ever, so far there was no evidence for increased toxicity after 
early administration of ﬁ  lgrastim.72
For pegfilgrastim, the best scheduling was day 1. 
However, there were no signiﬁ  cant differences between 
the three timing options for both MCC and AOC. Although 
with insigniﬁ  cantly lower MCC and higher AOC, the tim-
ing day 0 was the worst. Nadir occurred signiﬁ  cantly earlier 
than in the day 1 and 2 timing schedules. Again, in clinical 
practice it is not recommended to apply pegﬁ  lgrastim directly 
after chemotherapy, however there is a lack of clinical 
evidence regarding worse side effects.71,73,74 We found that 
for pegﬁ  lgrastim the effect of timing is not as critical as 
it is for ﬁ  lgrastim. One reason could be that bone marrow Biologics: Targets & Therapy 2009:3 35
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stimulation with respect to maturation or release of bone 
marrow reserve is a bit lower for pegﬁ  lgrastim than for ﬁ  l-
grastim. This could be explained by an interaction of G-CSF 
receptors and pegylation.75 We also plan further experiments 
with respect to this issue. On the other hand, from model 
simulations we expect that timing of pegﬁ  lgrastim might 
play a role for low dose applications which were not tested 
in our experiments.
We compared the best ﬁ  lgrastim and pegﬁ  lgrastim sched-
ules and found no differences with respect to MCC and ANC. 
This implies that ﬁ  lgrastim is equivalent to pegﬁ  lgrastim 
when used properly in accordance with other clinical obser-
vations by many authors.20,45–47 Since we applied the same 
protein mass in all of the schedules, we conclude that the 
superior pharmacokinetic properties of pegﬁ  lgrastim (lon-
ger half-life) are diminished to some extent by the inferior 
potency of bone marrow stimulation.
The effect of G-CSF on monocyte dynamics has not been 
as well investigated as it has for granulocytes. Some stud-
ies observed a beneﬁ  cial effect of G-CSF on monocytosis 
under infection or chemotherapy.76,77 It is believed that this 
effect is based on the stimulation of common precursors 
or the synergistic action with the endogenous macrophage 
CSF. In our study, the results of different G-CSF sched-
ules on monocyte dynamics were roughly the same as for 
granulocyte dynamics. In other words, both ﬁ  lgrastim day 1, 
4 × 10 μg and pegﬁ  lgrastim day 1 were the best schedules 
with respect to monocytotoxicity in accordance to our ﬁ  nd-
ings for granulotoxicity.
We found no differences in lymphocyte toxicity between 
no G-CSF, the ﬁ  lgrastim schedules and the pegﬁ  lgrastim 
schedules. This might be not surprising, since G-CSF is 
considered to be lineage speciﬁ  c. On the other hand, there 
is some evidence that lymphopoiesis is also affected by 
G-CSF.78,79 There are also reports of a more favorable effect 
of pegﬁ  lgrastim on lymphopoiesis compared to ﬁ  lgrastim.80 
However, we could not ﬁ  nd these effects in our own data 
probably due to the smaller size of the effects. The only 
evidence found was a small but signiﬁ  cant shift towards 
earlier occurrence of lymphocyte nadir for G-CSF schedules 
starting at day 0. The latter effect as been found throughout 
all three lineages considered.
The results from our preclinical mouse model show 
that there is a high potential of optimizing G-CSF dosing 
and timing schedules for ﬁ  lgrastim but not for timing of 
pegﬁ  lgrastim. Despite of the wide use of pegﬁ  lgrastim as the 
more convenient G-CSF treatment, we believe that ﬁ  lgrastim 
will not vanish from clinical practice since corresponding 
schedules can be adapted and individualized more easily 
according to the clinical situation.
However, optimization of G-CSF prophylaxis also 
depends on the chemotherapeutic regimens used. Again, 
it is not possible to perform analogous experiments for all 
kinds of chemotherapeutic drugs. Hence, we aim to develop a 
biomathematical model of murine hematopoiesis under che-
motherapy in analogy to our established model for humans. 
In order to construct a model which permits reliable quanti-
tative predictions of hematotoxicity, precise data regarding 
the time courses of concomitantly measured blood cells and 
cytokine are required. Additionally, the analysis of bone 
marrow dynamics after the application of cytokines and/or 
chemotherapeutic drugs would also be needed.59
The planned models will allow quantitative predictions 
about the time course of bone marrow cell stages, circulating 
blood cells and cytokine concentrations for chemotherapeutic 
regimens not yet tested. Systematic model simulations of 
variable therapy parameters can lead to predictions about 
eg optimal application schedules of hematopoietic growth 
factors. Because of a larger database especially with respect 
to bone marrow cell dynamics in mice, we plan to construct 
these models in mice and humans in parallel by assuming 
the same physiological mechanisms but different model 
parameters.
Hence, our study is a part of a series of ongoing experi-
ments aiming to provide the data necessary for our systems – 
biologic approach.
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